JP6827165B2 - Feed composition for boosting immunity of suckling livestock - Google Patents
Feed composition for boosting immunity of suckling livestock Download PDFInfo
- Publication number
- JP6827165B2 JP6827165B2 JP2017121726A JP2017121726A JP6827165B2 JP 6827165 B2 JP6827165 B2 JP 6827165B2 JP 2017121726 A JP2017121726 A JP 2017121726A JP 2017121726 A JP2017121726 A JP 2017121726A JP 6827165 B2 JP6827165 B2 JP 6827165B2
- Authority
- JP
- Japan
- Prior art keywords
- livestock
- milk
- feeding
- immunity
- absorption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000144972 livestock Species 0.000 title claims description 49
- 230000036039 immunity Effects 0.000 title claims description 29
- 239000000203 mixture Substances 0.000 title claims description 27
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 25
- 229940035436 maltitol Drugs 0.000 claims description 24
- 235000010449 maltitol Nutrition 0.000 claims description 24
- 239000000845 maltitol Substances 0.000 claims description 24
- 238000010521 absorption reaction Methods 0.000 claims description 22
- 235000020243 first infant milk formula Nutrition 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 241000283690 Bos taurus Species 0.000 claims description 19
- 108060003951 Immunoglobulin Proteins 0.000 claims description 17
- 102000018358 immunoglobulin Human genes 0.000 claims description 17
- 230000002708 enhancing effect Effects 0.000 claims description 14
- 241000283707 Capra Species 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 9
- 241000283086 Equidae Species 0.000 claims description 9
- 241001494479 Pecora Species 0.000 claims description 9
- 241000282887 Suidae Species 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- 230000035611 feeding Effects 0.000 description 35
- 235000013336 milk Nutrition 0.000 description 26
- 239000008267 milk Substances 0.000 description 26
- 210000004080 milk Anatomy 0.000 description 26
- 244000309466 calf Species 0.000 description 13
- 239000000047 product Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- -1 IgM Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000003977 dairy farming Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Images
Description
本発明は、哺乳期家畜の免疫力増強用飼料組成物等に関するものである。詳細には、哺乳期家畜(牛、馬、豚、羊、山羊など)において、その免疫力を増強させるための飼料組成物、飼養方法等に関するものである。 The present invention relates to a feed composition for enhancing immunity of suckling livestock and the like. More specifically, the present invention relates to a feed composition, a feeding method, and the like for enhancing immunity in suckling livestock (cattle, horses, pigs, sheep, goats, etc.).
酪農、畜産業界において、哺乳期家畜の死亡は飼養技術や家畜医療技術が向上した現在においても依然として多く、その死亡率の低下が要望されている。例えば、牛について、北海道においては生後1ヶ月以内に1割の子牛が死亡しており、関係機関などが一体となって飼養環境の改善等に取り組んでいる現状にある。 In the dairy and livestock industries, the number of deaths of livestock during the feeding period is still high even now that the feeding technology and the livestock medical technology have improved, and there is a demand for a reduction in the mortality rate. For example, with regard to cattle, 10% of calves have died within the first month of life in Hokkaido, and related organizations are currently working together to improve the breeding environment.
なお、子牛は感染症に弱く、下痢や肺炎による育成中の死亡は、そのほとんどが哺乳期間中に発生しているとされている。子牛などの哺乳期家畜の死亡率低減にあたっては、飼養環境(特に衛生環境)を良好にすると共に、個体の健康(特に免疫抵抗性)増進を図っていくことが重要と考えられている。 In addition, calves are vulnerable to infectious diseases, and it is said that most of the deaths during breeding due to diarrhea and pneumonia occur during the lactation period. In order to reduce the mortality rate of suckling livestock such as calves, it is considered important to improve the breeding environment (especially the sanitary environment) and to improve the health of the individual (especially immune resistance).
この個体の免疫抵抗性増進(免疫力増強)については、例えば子牛の場合は、初乳の給与により、免疫抗体(IgG、IgM、IgAなどの免疫グロブリン)が母牛から子牛へ移行することで免疫力を獲得する。出生後から約4〜8週齢頃までの子牛は、感染症などに抵抗するための抗体を産生することができず、免疫抗体を多量に含んだ初乳を摂取することにより初めて母由来の免疫抗体を獲得することができ、これは受動免疫と呼ばれる。受動免疫の移行が不全な子牛については、罹病率や死亡率が増加するため、受動免疫移行不全の診断方法なども提案されている(非特許文献1)。 Regarding the enhancement of immune resistance (immunity enhancement) of this individual, for example, in the case of calves, immune antibodies (immunoglobulins such as IgG, IgM, IgA) are transferred from mother cows to calves by feeding the first milk. By doing so, you gain immunity. Calves from birth to about 4 to 8 weeks of age are unable to produce antibodies to resist infectious diseases, etc., and are derived from the mother only by ingesting first milk containing a large amount of immune antibodies. Immune antibodies can be obtained, which is called passive immunity. Since the morbidity and mortality rates of calves with deficient passive immunity transfer increase, a method for diagnosing passive immunity deficiency has also been proposed (Non-Patent Document 1).
なお、免疫抗体移行の仕組みは、馬、豚、羊、山羊などの家畜も牛と同様で、母体の胎盤を通じて母から子へ抗体は移行せず、初乳により移行する。そして、哺乳期家畜の免疫グロブリン賦活活性(特許文献1)や、免疫グロブリン吸収促進活性(特許文献2)などを有する成分が見出されており、また、IgGを含む初乳を濃縮することでIgGを高含有したものも市販されているが、当業界においては、哺乳期家畜の免疫力を増強できる更なる成分等の開発など、多方面からの総合的な取り組みが引き続き望まれていた。 The mechanism of immune antibody transfer is the same for domestic animals such as horses, pigs, sheep, and goats, and the antibody does not transfer from the mother to the offspring through the placenta of the mother, but is transferred by the first milk. Then, a component having an immunoglobulin activating activity (Patent Document 1) and an immunoglobulin absorption promoting activity (Patent Document 2) of suckling livestock has been found, and by concentrating the primary milk containing IgG. Although high IgG-rich substances are commercially available, comprehensive efforts from various fields such as development of further components capable of enhancing the immunity of suckling livestock have been desired in the industry.
一方、マルチトールは、高純度の麦芽糖水飴(主成分:麦芽糖)を触媒の存在下で高圧接触還元(水素添加)する方法などにより得られる糖アルコールであり、それは砂糖に似た甘味質を有する難消化性糖質であることなどから低カロリー素材として各種健康食品などに広く使用されている。また、マルチトールを動物用飼料に利用した例(特許文献3)もあるが、さらにその用途を広げ、市場を拡大することが望まれている。 On the other hand, maltitol is a sugar alcohol obtained by high-pressure catalytic reduction (hydrogenation) of high-purity maltose starch syrup (main component: maltose) in the presence of a catalyst, and it has a sweetness similar to sugar. Since it is a resistant sugar, it is widely used in various health foods as a low-calorie material. There is also an example of using maltitol as animal feed (Patent Document 3), but it is desired to further expand its use and expand the market.
しかし、マルチトールを哺乳期家畜へ給与又は経口投与した際の免疫力等に対する影響に関しては、現在までのところ知られていない。 However, the effect on immunity and the like when maltitol is fed or orally administered to suckling livestock has not been known so far.
本発明は、食経験の豊富な成分を用いて、簡便且つ効果的で安全性の高い、哺乳期家畜(牛、馬、豚、羊、山羊など)の免疫力を増強させるための飼料組成物、哺乳期家畜の飼養方法等を提供することを目的とする。 The present invention is a feed composition for enhancing the immunity of feeding livestock (cattle, horses, pigs, sheep, goats, etc.), which is simple, effective and highly safe, using ingredients having abundant eating experience. , The purpose is to provide a method for raising livestock during the feeding period.
上記目的を達成するため、本発明者らは鋭意研究の結果、マルチトールを有効成分として含有する飼料組成物等を哺乳期家畜に給与又は経口投与することで、その免疫力を増強させ、哺乳期家畜の死亡率低減や感染症予防などもできることを見出し、本発明を完成した。 In order to achieve the above object, as a result of diligent research, the present inventors enhanced their immunity by feeding or orally administering a feed composition or the like containing martitol as an active ingredient to livestock during the feeding period, thereby enhancing the feeding power. The present invention has been completed by finding that it is possible to reduce the mortality rate of livestock and prevent infectious diseases.
すなわち、本発明の実施形態は次のとおりである。
(1)マルチトールを有効成分とする(有効成分として含有する)、哺乳期家畜の免疫力増強用飼料組成物(特に、免疫力増強による死亡率低減及び/又は感染症予防用飼料組成物)。
(2)飼料組成物が初乳及び/又は人工初乳を含有することを特徴とする、(1)に記載の組成物。
(3)免疫力増強が、免疫グロブリン吸収促進である(1)又は(2)に記載の組成物。
(4)免疫グロブリン吸収促進が、IgG吸収促進である(3)に記載の組成物。
(5)家畜が牛、馬、豚、羊、山羊から選ばれる1以上である、(1)〜(4)のいずれか1つに記載の飼料組成物。
That is, the embodiment of the present invention is as follows.
(1) Feed composition for enhancing immunity of suckling livestock containing Martinol as an active ingredient (containing as an active ingredient) (particularly, feed composition for reducing mortality rate and / or preventing infectious diseases by enhancing immunity) ..
(2) The composition according to (1), wherein the feed composition contains primary milk and / or artificial primary milk.
(3) The composition according to (1) or (2), wherein the enhancement of immunity is the promotion of immunoglobulin absorption.
(4) The composition according to (3), wherein the promotion of immunoglobulin absorption is the promotion of IgG absorption.
(5) The feed composition according to any one of (1) to (4), wherein the livestock is one or more selected from cattle, horses, pigs, sheep, and goats.
(6)マルチトール(例えば、マルチトールを含有する飼料組成物又は医薬組成物)を哺乳期家畜に給与又は経口投与することを特徴とする、哺乳期家畜の免疫力増強方法。
(7)マルチトールを哺乳期家畜に給与又は経口投与することを特徴とする、哺乳期家畜の免疫力増強による死亡率低減及び/又は感染症予防方法。
(8)免疫力増強が、免疫グロブリン吸収促進である(6)又は(7)に記載の方法。
(9)免疫グロブリン吸収促進が、IgG吸収促進である(8)に記載の方法。
(10)出生後48時間以内に給与又は経口投与することを特徴とする、(6)〜(9)のいずれか1つに記載の方法。
(11)初乳又は人工初乳にマルチトールを混合して給与することを特徴とする、(6)〜(10)のいずれか1つに記載の方法。
(12)家畜が牛、馬、豚、羊、山羊から選ばれる1以上である、(6)〜(11)のいずれか1つに記載の方法。
(13)哺乳期において(6)〜(11)のいずれか1つに記載の方法により飼養された乳牛(泌乳牛)から搾乳することを特徴とする、牛乳の生産方法。
(6) A method for enhancing immunity of a suckling livestock, which comprises feeding or orally administering maltitol (for example, a feed composition or a pharmaceutical composition containing maltitol) to the feeding livestock.
(7) A method for reducing mortality and / or preventing infectious diseases by enhancing immunity of suckling livestock, which comprises feeding or orally administering maltitol to feeding livestock.
(8) The method according to (6) or (7), wherein the enhancement of immunity is the promotion of immunoglobulin absorption.
(9) The method according to (8), wherein the promotion of immunoglobulin absorption is the promotion of IgG absorption.
(10) The method according to any one of (6) to (9), which comprises feeding or orally administering the drug within 48 hours after birth.
(11) The method according to any one of (6) to (10), which comprises feeding maltitol mixed with first milk or artificial first milk.
(12) The method according to any one of (6) to (11), wherein the livestock is one or more selected from cattle, horses, pigs, sheep, and goats.
(13) A method for producing milk, which comprises milking from a dairy cow (lactating cow) bred by the method according to any one of (6) to (11) during the lactation period.
本発明によれば、哺乳期家畜にとって安全性の高い成分を給与又は経口投与するだけで、簡便且つ効果的にその免疫力を増強させ、哺乳期家畜の死亡率低減や感染症予防などもできる。また、マルチトールは、砂糖や水飴同様、広く加工食品原料として利用されており、その家畜飼養への利用はし易く、これによりマルチトールの新規用途による市場拡大効果も期待できる。 According to the present invention, it is possible to easily and effectively enhance the immunity, reduce the mortality rate of the suckling livestock, prevent infectious diseases, etc. simply by feeding or orally administering a component highly safe for the feeding livestock. .. In addition, maltitol, like sugar and starch syrup, is widely used as a raw material for processed foods, and it is easy to use for livestock breeding, which is expected to have the effect of expanding the market due to new uses of maltitol.
まず、本発明においては、マルチトールを哺乳期家畜の免疫力増強用飼料組成物等(サプリメントや医薬組成物などでも良い)の有効成分として使用する。マルチトールは、麦芽糖を還元(水素添加)する方法などにより得られる糖アルコールであり、必要に応じて乾燥粉末状、顆粒状、液体状、ペースト状等のものを使用することができ、その使用形態は特段限定されるものではない。また、マルチトールの純品(精製品)だけでなく、粗精製品や市販品の使用も除外されないが、一定以上(例えば10%以上)の含有率まで精製されたものを用いることが好ましい。 First, in the present invention, maltitol is used as an active ingredient of a feed composition for enhancing immunity of suckling livestock (supplements, pharmaceutical compositions, etc. may be used). Maltitol is a sugar alcohol obtained by a method of reducing (hydrogenating) maltose, and if necessary, dry powder, granules, liquid, paste, etc. can be used, and the use thereof. The form is not particularly limited. Further, the use of not only pure maltitol products (refined products) but also crude products and commercial products is not excluded, but it is preferable to use products refined to a certain content (for example, 10% or more).
そして、このマルチトールを有効成分として含有する飼料組成物等を、哺乳期家畜へ給与又は経口投与を行う。給与又は経口投与量は、子牛で例示すると、1日に2回の給与又は経口投与において1回あたりマルチトールとして1〜50g/頭、好ましくは5〜20g/頭程度である。特に、出生後12時間以内に2回投与し、出生後48時間までに20〜100g/頭以上を給与又は経口投与するのが好ましい。なお、この量は1日当たり体重1kgにつき160〜1400mg程度である。給与・投与の回数、マルチトールの量などは、上記を参考に適宜調節が可能である。子牛以外の家畜についても、当該投与量と同じでも良いし、この数値から体重等による所要の換算等を行って投与量を設定してもよい。また、給与又は経口投与開始時期については、出生後48時間以内に、好ましくは36時間以内に、さらに好ましくは24時間以内に、最も好ましくは1時間以内に給与又は経口投与を開始するのが好適例として挙げられる。給与(投与)回数に応じて、適宜マルチトールの量を調節しても良い。 Then, the feed composition or the like containing this maltitol as an active ingredient is fed or orally administered to the suckling livestock. For example, in calves, the feeding or oral dose is about 1 to 50 g / head, preferably about 5 to 20 g / head as maltitol per feeding or oral administration twice a day. In particular, it is preferable to administer twice within 12 hours after birth, and to feed or orally administer 20 to 100 g / head or more by 48 hours after birth. This amount is about 160 to 1400 mg per 1 kg of body weight per day. The number of feedings / administrations, the amount of maltitol, etc. can be adjusted as appropriate with reference to the above. For livestock other than calves, the dose may be the same as the dose, or the dose may be set by performing the required conversion based on the body weight or the like from this value. Regarding the start time of feeding or oral administration, it is preferable to start feeding or oral administration within 48 hours after birth, preferably within 36 hours, more preferably within 24 hours, and most preferably within 1 hour. Take as an example. The amount of maltitol may be appropriately adjusted according to the number of feedings (administration).
なお、本発明の対象となる家畜としては、乳や肉などをヒトが利用する反芻家畜(乳牛、肉牛、羊、山羊など)、馬、豚などが例示される。本発明は、免疫抗体移行の仕組みが受動免疫である家畜の哺乳期(例えば、牛では出生後から約4〜8週齢頃まで)で効果を発揮することが特徴である。 Examples of livestock to be the subject of the present invention include ruminant livestock (dairy cows, beef cattle, sheep, goats, etc.), horses, pigs, etc., in which milk and meat are used by humans. The present invention is characterized in that the mechanism of immune antibody transfer is passive immunity, and is effective during the feeding period of livestock (for example, in cattle, from the time of birth to about 4 to 8 weeks of age).
本発明に係る飼料組成物等の形態としては、例えばマルチトールと他の飼料原料等を混合して粉末状、顆粒状、ペースト状、液状などとした粉末剤、顆粒剤、シロップ剤、液剤等の製剤として給与又は経口投与しても良いが、免疫グロブリン(IgG、IgM、IgAなど)を多く含有する初乳や人工初乳、あるいは、代用乳や人工乳などにマルチトールを混合して飼料組成物として給与するのが好ましい。特に、マルチトールと共に、免疫グロブリンを出生後24時間までに体重1kgにつき1〜10g程度供給できるような組成物とするのが好ましい。また、マルチトール以外の免疫力増強成分(例えばラフィノースやDFAなど)や他の機能性成分、乳酸菌生菌などを併用することも特段の制約はなく、さらには、マルチトールを別途単独で給与又は経口投与しても差し支えない。 Examples of the form of the feed composition and the like according to the present invention include powders, granules, syrups, liquids and the like obtained by mixing colostrum and other feed raw materials into powder, granules, pastes, liquids and the like. Although it may be fed or orally administered as a preparation of the above, it is a feed obtained by mixing multitoll with milk replacer or artificial milk containing a large amount of immunoglobulin (IgG, IgM, IgA, etc.) or milk replacer or artificial milk. It is preferably fed as a composition. In particular, it is preferable to prepare a composition that can supply about 1 to 10 g of immunoglobulin per 1 kg of body weight by 24 hours after birth together with maltitol. In addition, there are no particular restrictions on the combined use of immunity-enhancing components (such as raffinose and DFA) other than maltitol, other functional components, and live lactic acid bacteria. Furthermore, maltitol is separately fed or fed separately. It may be administered orally.
ここで、本発明において、初乳とは、分娩後初めてもしくは2回目に搾乳される乳汁を意味し、人工初乳とは、初乳に近似した組成の哺乳家畜用飼料を意味する。また、代用乳とは、脱脂粉乳を主原料とし液状に溶解して給与する飼料を意味し、人工乳とは、固形状で給与する代用乳以外の配合飼料を意味する。 Here, in the present invention, the first milk means milk that is milked for the first time or the second time after delivery, and the artificial first milk means a feed for livestock for livestock having a composition similar to that of the first milk. The milk replacer means a feed containing skim milk powder as a main raw material, dissolved in a liquid form and fed, and the artificial milk means a mixed feed other than the milk replacer fed in a solid form.
このようにして、哺乳期家畜にマルチトールを給与又は経口投与することで、その免疫力を増強させ、特に免疫グロブリン吸収促進を促し、哺乳期家畜の死亡率低減や感染症予防などもできる。これは、マルチトールの新規用途発明であり、マルチトールの市場拡大も期待できる。 In this way, by feeding or orally administering Martinol to the suckling livestock, the immunity thereof can be enhanced, particularly the promotion of immunoglobulin absorption can be promoted, the mortality rate of the feeding livestock can be reduced, and infectious diseases can be prevented. This is an invention for new use of maltitol, and the market for maltitol can be expected to expand.
さらに、哺乳期家畜にマルチトールを給与又は経口投与することで、成体までにおいて個体の健康増進を図ることができ、例えば乳牛(泌乳牛)では、成牛の乳生産量向上や乳質改善など牛乳生産にも好ましい効果が得られる。 Furthermore, by feeding or orally administering Martinol to livestock during the lactation period, it is possible to improve the health of individuals up to the adult stage. For example, in dairy cows (lactating cows), milk such as improving milk production and milk quality of adult cows A favorable effect is also obtained in production.
以下、本発明の実施例について述べるが、本発明はこれらの実施例のみに限定されるものではなく、本発明の技術的思想内においてこれらの様々な変形が可能である。 Examples of the present invention will be described below, but the present invention is not limited to these examples, and various modifications thereof are possible within the technical idea of the present invention.
マルチトール添加人工初乳を給与した哺乳期家畜の免疫グロブリン吸収及び血清中の免疫グロブリン濃度に対する効果を確認するため、以下の試験を実施した。 The following tests were carried out to confirm the effect on immunoglobulin absorption and serum immunoglobulin concentration of suckling livestock fed with Martinol-added artificial first milk.
供試家畜はホルスタイン種乳牛の雄子牛18頭とし、1試験区あたり6頭ずつに分け、 対照区は人工初乳(ヘッドスタート(登録商標、IgG60g/袋(225g)含有)、バイエル薬品株式会社製品)又は代用乳(みるくる(登録商標)、明治飼糧株式会社製品)のみ給与、本発明区(MAL区)は人工初乳又は代用乳+マルチトール(Amalty MR−50(登録商標)、三菱商事フードテック株式会社製品)給与(マルチトールの添加量は18g/回)、比較対象区(FOS区)として人工初乳又は代用乳+フラクトオリゴ糖(メイオリゴ−P(登録商標)、株式会社明治製品)給与(フラクトオリゴ糖の添加量は18g/回)を出生から7日後まで行った。なお、3処理区のいずれも、給与は次のとおり行った。 The test livestock were 18 male and female Holstein cows, divided into 6 per test group, and the control group was artificial first milk (head start (registered trademark, IgG60 g / bag (225 g) included), Bayer Pharmaceutical Co., Ltd. Product) or milk replacer (Mirukuru (registered trademark), Meiji Foods Co., Ltd. product) only, the present invention zone (MAL section) is artificial first milk or milk replacer + milk replacer (Amalty MR-50 (registered trademark), Mitsubishi Shoji Food Tech Co., Ltd. product) Salary (multi-toll added amount is 18 g / time), artificial first milk or milk replacer + fructo-oligosaccharide (Meioligo-P (registered trademark), Meiji products) as comparison target group (FOS group) ) Feeding (the amount of fructo-oligosaccharide added was 18 g / dose) was performed from birth to 7 days after birth. The salaries of all three treatment areas were as follows.
1.出生1時間以内に、IgGを120g含む人工初乳を2L給与
2.出生10時間後に、IgGを120g含む人工初乳を2L給与
3.出生24時間後に、代用乳を2L給与
4.出生36時間後に、代用乳を2L給与
5.出生3日以降は、1日2回、代用乳2L給与
1. 1. Within 1 hour of birth, feed 2 L of artificial first milk containing 120 g of IgG. 3. 10 hours after birth, feed 2 L of artificial first milk containing 120 g of IgG. 2. 24 hours after birth, give 2L of milk replacer. 3. Salary 2L of milk replacer 36 hours after birth. After 3 days of birth, 2L of milk replacer twice a day
ここで、本試験において、親牛から搾乳した初乳を使用せず、人工初乳及び代用乳を使用した目的は、初乳の差による影響を排除するためである。また、本試験においては具体的な商品名が挙げられているが、これは供試品の素性を示すためであり、個々の商品の優劣を表すものではない。 Here, in this test, the purpose of using artificial first milk and milk replacer instead of using the first milk milked from the parent cow is to eliminate the influence of the difference in the first milk. In addition, although specific product names are given in this test, this is to indicate the identity of the specimen and does not indicate the superiority or inferiority of each product.
そして、出生1時間以内(0時間として扱う)〜36時間後については給与直前に9mlの採血を実施し、出生3日以降については4日目と7日目に同様の採血を実施し、それぞれ血清IgG濃度をELISA法により測定した。同時に、みかけのIgG吸収率 (AEA:Apparent Efficiency of Absorption)も、出生24時間後の血清IgG濃度に基づき、以下の式で算出した。 Then, 9 ml of blood was collected immediately before feeding within 1 hour (treated as 0 hours) to 36 hours after birth, and the same blood collection was performed on the 4th and 7th days after the 3rd day of birth, respectively. Serum IgG concentration was measured by ELISA. At the same time, the apparent IgG absorption rate (AEA: Apparent Efficiency of Absorption) was also calculated by the following formula based on the serum IgG concentration 24 hours after birth.
AEA=(体重(kg)×8.6%×血清IgG濃度(g/L))÷IgG給与量×100 AEA = (body weight (kg) x 8.6% x serum IgG concentration (g / L)) / IgG feed amount x 100
なお、この給与と採血のタイミングをまとめたものを下記表1に、各区の子牛の出生時体重(平均)及びIgG給与量(総量)を下記表2に示した。 Table 1 below summarizes the timing of this feeding and blood collection, and Table 2 below shows the birth weight (average) and IgG feeding amount (total amount) of calves in each ward.
この試験結果を図1及び図2に示した。まず、図1において、血清IgG濃度は、出生してから10時間後ではそれぞれの区において有意な差は認められず、出生してから24時間後(1日後)より本発明区(MAL区:黒丸及び一点鎖線)が対照区(白抜き三角及び実線)及び比較対象区(FOS区:黒四角及び点線)よりも有意に高くなった。そして、36時間後、4日後、7日後においても同様であった。なお、対照区と比較対象区(FOS区)では、試験期間全体で有意な差は認められなかった。なお、有意水準は5%である。
The test results are shown in FIGS. 1 and 2. First, in FIG. 1, no significant difference was observed in the serum IgG concentration in each
また、出生24時間目におけるみかけのIgG吸収率についても、図2のとおり、本発明区(MAL区)が対照区及び比較対象区(FOS区)よりも有意に高くなった。これも、対照区と比較対象区(FOS区)では有意な差は認められなかった。なお、これも有意水準は5%である。 In addition, as shown in FIG. 2, the apparent IgG absorption rate at the 24th hour of birth was also significantly higher in the present invention group (MAL group) than in the control group and the comparative group (FOS group). Again, no significant difference was observed between the control group and the comparison target group (FOS group). The significance level of this is also 5%.
これらの結果から、哺乳期子牛にマルチトールをIgG含有人工初乳あるいは代用乳とともに給与することにより、そのIgGの吸収を促進することができること、ブドウ糖に果糖が2〜5分子結合したオリゴ糖であるフラクトオリゴ糖には同様の効果が認められなかったこと(糖質の種類によって哺乳期家畜の免疫増強活性に大きな違いが認められること)が確認された。 Based on these results, it is possible to promote the absorption of IgG by feeding multitoll with IgG-containing artificial priming milk or milk replacer to suckling calves, and oligosaccharides in which 2 to 5 molecules of fructose are bound to glucose. It was confirmed that the same effect was not observed with fructose oligosaccharide (a large difference was observed in the immunopotentiating activity of suckling livestock depending on the type of sugar).
本発明を要約すれば、以下の通りである。 The present invention can be summarized as follows.
本発明は、食経験の豊富な成分を用いて、簡便且つ効果的で安全性の高い、哺乳期家畜(牛、馬、豚、羊、山羊など)の免疫力を増強させるための飼料組成物、哺乳期家畜の飼養方法等を提供することを目的とする。 The present invention is a feed composition for enhancing the immunity of feeding livestock (cattle, horses, pigs, sheep, goats, etc.), which is simple, effective and highly safe, using ingredients having abundant eating experience. , The purpose is to provide a method for raising livestock during the feeding period.
そして、マルチトールを有効成分として含有する飼料組成物等を哺乳期家畜に給与又は経口投与することで、その免疫力を増強させ(特に免疫グロブリン吸収促進を促し)、また、哺乳期家畜の死亡率低減や感染症予防などもでき、効率的な酪農、畜産経営を行うことができる。 Then, by feeding or orally administering a feed composition or the like containing martitol as an active ingredient to the suckling livestock, the immunity thereof is enhanced (particularly promoting the absorption of immunoglobulin), and the suckling livestock dies. It is possible to reduce the rate and prevent infectious diseases, and to carry out efficient dairy farming and livestock farming.
Claims (12)
The method according to any one of claims 6 to 11, wherein the livestock is one or more selected from cattle, horses, pigs, sheep, and goats.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017121726A JP6827165B2 (en) | 2017-06-21 | 2017-06-21 | Feed composition for boosting immunity of suckling livestock |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017121726A JP6827165B2 (en) | 2017-06-21 | 2017-06-21 | Feed composition for boosting immunity of suckling livestock |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019004726A JP2019004726A (en) | 2019-01-17 |
JP6827165B2 true JP6827165B2 (en) | 2021-02-10 |
Family
ID=65025445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017121726A Active JP6827165B2 (en) | 2017-06-21 | 2017-06-21 | Feed composition for boosting immunity of suckling livestock |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6827165B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111919817A (en) * | 2020-08-18 | 2020-11-13 | 爱福洋生物科技(江苏)有限公司 | Breeding method for improving meat quality and yield of Jiangsu white goats |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2887768B2 (en) * | 1991-06-20 | 1999-04-26 | 東和化成工業株式会社 | Animal feed containing calcium and crude fiber |
CN103583840A (en) * | 2012-08-15 | 2014-02-19 | 邱世连 | Novel milk replacing feed for suckling pigs |
-
2017
- 2017-06-21 JP JP2017121726A patent/JP6827165B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2019004726A (en) | 2019-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108541817A (en) | One broad sow compound premix | |
JP2023123516A (en) | Use of human milk oligosaccharide in fattening calf | |
JP6827165B2 (en) | Feed composition for boosting immunity of suckling livestock | |
CN106721305A (en) | It is a kind of to improve compositions of additives of body condition or its production performance and preparation method thereof after Farrowing | |
JP5584124B2 (en) | Anti-coccidial composition | |
RU2522352C2 (en) | Method of feeding cows for increasing biological usefulness and quality of milk | |
EP3291691A2 (en) | The use of nitrate for improving the reproductive performance of monogastric mammals | |
EP0914831A2 (en) | Biological product for preventive or therapeutic oral administration against canine parvovirosis | |
JP7066888B2 (en) | Method of increasing milk yield and milk fat content of ruminant livestock | |
JP4880508B2 (en) | Immunoglobulin absorption promoting composition | |
CN111903612B (en) | Feeding method for breeding donkey in northern farming-grazing staggered manner | |
JP2014132028A (en) | Preventive agent for postpartum ketosis in livestock | |
JP5894615B2 (en) | Heat stress reducing agent for livestock | |
EP1776956A1 (en) | Preventive and/or therapeutic agent for calcipenia | |
Karamayev et al. | Quality of colostrum in dairy breed cows with different dairy productivity | |
JP7444707B2 (en) | Livestock colostrum quality improving agent and method | |
Upadhaya et al. | Effect of plant extract YGF251 on growth performance, reproductive performance and insulin like growth factor secretion in primiparous and multiparous sows | |
JP5926282B2 (en) | Improved mineral compositions and methods of use | |
de Oliveira Nascimento et al. | The Importance of artificial breastfeeding in goat breeding–literature review | |
JP7313519B1 (en) | IgA production promoter and feed composition for promoting IgA production | |
RU2716211C1 (en) | Method for growing of broiler chickens | |
Sampath et al. | Impact of artificial colostrum supplement on the growth performance and blood profile in piglets | |
JP4482493B2 (en) | Rotavirus infection / proliferation inhibitor | |
JP5248438B2 (en) | Ruminant milk production improver | |
Jacobsson et al. | Blood selenium in a beef herd affected with muscular degeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190701 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200729 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200811 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201008 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6827165 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |